ERX-963

Phase 1Small molecule

EExpansion Therapeutics, Inc.

ERX-963 is one of 10 small molecule programs targeting Myotonic Dystrophy Type 1. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Myotonic Dystrophy Type 1Active, not recruiting

Myotonic Dystrophy Type 1Phase 1

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Myotonic Dystrophy Type 1

#DrugCompanyPhaseTrials

Mexitil

Boehringer Ingelheim

Phase 3

2 2

Ritalin

Novartis

Phase 2

1 3

Wakix

HHarmony Biosciences Management, Inc.

Phase 2

1 4

DYNE-101

DDyne Therapeutics

Phase 3

1 5

Ranexa

MMenarini International Operations Luxembourg SA

Phase 1

1 6

Rhigf-I/rhigfbp-3

Takeda

Phase 2

1 7

AOC 1020

AAvidity Biosciences, Inc.

Phase 2

2 8

Sefaxersen (RO7434656)

PGN-EDODM1

3 10

ERX-963

EExpansion Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Myotonic Dystrophy Type 11 trial

Safety, Tolerability and Pharmacokinetics of ERX-963 in Adults With Myotonic Dystrophy Type 1

Completed·EExpansion Therapeutics, Inc.·Phase 1·NCT03959189·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ERX-963. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ERX-963 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ERX-963. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Expansion Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: EExpansion Therapeutics, Inc.

ERX-963

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Myotonic Dystrophy Type 11 trial

References

Drug Info

Quick Facts

Related News